Application of contrast-enhanced CT radiomics in prediction of early recurrence of locally advanced oesophageal squamous cell carcinoma after trimodal therapy

Sun Tang1†, Jing Ou1†, Jun Liu2, Yu-ping Wu1, Chang-qiang Wu2, Tian-wu Chen1*, Xiao-ming Zhang1, Rui Li1, Meng-jie Tang1, Li-qin Yang1, Bang-guo Tan1, Fu-lin Lu1 and Jiani Hu3

Abstract

Background: Early recurrence of oesophageal squamous cell carcinoma (SCC) is defined as recurrence after surgery within 1 year, and appears as local recurrence, distant recurrence, and lymph node positive and disseminated recurrence. Contrast-enhanced computed tomography (CECT) is recommended for diagnosis of primary tumor and initial staging of oesophageal SCC, but it cannot be used to predict early recurrence. It is reported that radiomics can help predict preoperative stages of oesophageal SCC, lymph node metastasis before operation, and 3-year overall survival of oesophageal SCC patients following chemoradiotherapy by extracting high-throughput quantitative features from CT images. This study aimed to develop models based on CT radiomics and clinical features of oesophageal SCC to predict early recurrence of locally advanced cancer.

Methods: We collected electronic medical records and image data of 197 patients with confirmed locally advanced oesophageal SCC. These patients were randomly allocated to 137 patients in the training cohort and 60 in the test cohort. 352 radiomics features were extracted by delineating region-of-interest (ROI) around the lesion on CECT images and clinical signature was generated by medical records. The radiomics model, clinical model, the combined model of radiomics and clinical features were developed by radiomics features and/or clinical characteristics. Predicting performance of the three models was assessed with area under receiver operating characteristic curve (AUC), accuracy and F-1 score.

Results: Eleven radiomics features and/or six clinical signatures were selected to build prediction models related to recurrence of locally advanced oesophageal SCC after trimodal therapy. The AUC of integration of radiomics and clinical models was better than that of radiomics or clinical model for the training cohort (0.821 versus 0.754 or 0.679, respectively) and for the validation cohort (0.809 versus 0.646 or 0.658, respectively). Integrated model of radiomics and clinical features showed good performance in predicting early recurrence of locally advanced oesophageal SCC for both the training and validation cohorts (accuracy = 0.730 and 0.733, and F-1 score = 0.730 and 0.778, respectively).

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: The integrated model of CECT radiomics and clinical features may be a potential imaging biomarker to predict early recurrence of locally advanced oesophageal SCC after trimodal therapy.

Keywords: Esophageal neoplasms, Carcinoma Squamous Cell, Tomography X-ray computed, Recurrence, Therapeutics

Background
Oesophageal cancer is the eighth most common malignancies in the world [1], and squamous cell carcinoma (SCC) is the predominant histological type [2]. Locally advanced oesophageal SCC is defined as ≥ T2 or ≥ N1 carcinoma [3]. The survival rate of patients with locally advanced oesophageal SCC is extremely lower than that of patients with early oesophageal cancer, with the 5-year survival rate of only about 50% [4–6]. Previous studies indicate that the 1-year recurrence rate of oesophageal SCC after appropriate treatment may range 40-70% [7, 8]. As for early recurrence, it is defined as recurrence after surgery within 1 year, and appears as local recurrence, distant recurrence, and lymph node positive and disseminated recurrence [7, 9]. In order to improve the local survival, trimodal therapy including neoadjuvant chemotherapy, radiotherapy and surgery is often required in patients with locally advanced oesophageal cancer [10–12].

Currently, contrast-enhanced computed tomography (CECT) is commonly used for initial judging T and N staging of primary tumor [13], and 18 F-fluorodeoxyglucose–positron emission tomography CT (FDG-PET CT) is mainly used for judging M stage [14], but they cannot be used to predict early recurrence of locally advanced oesophageal SCC mainly based on the visually morphological and density features. Radiomics is a noninvasive tool to provide additional information by extracting high-throughput quantitative features from computed tomography (CT) images [15, 16]. It is reported that radiomics can be used to predict preoperative stages of oesophageal SCC [17], lymph node metastasis before operation [18], and 3-year overall survival of oesophageal SCC patients following chemoradiotherapy [19]. Although CT radiomics features have been applied and proved to be helpful for predicting early recurrence of hepatocellular carcinoma [20], there is no literature regarding the best way to use multiple imaging biomarkers as a predictive method to predict early recurrence of locally advanced oesophageal SCC. Thus, this study aimed to develop and validate novel models based on CT radiomics and clinical features of oesophageal SCC which can help predict early recurrence of locally advanced cancer after trimodal therapy so as to perform timely precise treatment to prevent the recurrence.

Methods
Patients
Ethical approval to perform this retrospective research was obtained from institution ethics committee of our hospital, and informed consent was waived. We retrospectively collected CT data and medical records of patients with locally advanced oesophageal SCC at our hospital from March 2016 to August 2018.

The enrolled patients needed to meet the following inclusion criteria: (1) oesophageal SCC patients underwent CECT and images with good quality were obtained within 2 weeks before the surgery; (2) the patients did not receive any tumor-related treatments (e.g., chemotherapy or radiotherapy) before undergoing the CT scans; (3) patients were confirmed no distant metastasis (M1) before surgery based on CT and/or PET-CT scans; (4) patients received standardized trimodal therapy, and were confirmed locally advanced oesophageal SCC and no residual tumor (R0) by postoperative pathology; and (5) patients were followed up for at least 1 year after trimodal therapy according to the latest edition of National Comprehensive Cancer Network (NCCN) guidelines [21]. In our study, 230 patients met the previous inclusion criteria. Of this cohort, 158 patients were confirmed no distant metastasis by CT before surgery, and the remained 72 patients in which the status of distant metastasis could not be well confirmed by CT were finally confirmed no distant metastasis by PET-CT scans. On CT, T staging was judged by the depth of tumor invasion, and N staging was mainly determined by the morphological and enhancement characteristics of lymph nodes [22, 23]. As for the surgical indications [21], the criteria for unresectable oesophageal cancer were as follows: (1) cT4b tumours with involvement of the heart, great vessels, trachea, or adjacent organs including liver, pancreas, lung and spleen were considered unresectable; (2) oesophageal SCC with multistation bulky lymphadenopathy was considered unresectable; or (3) oesophageal SCC with distant metastases including nonregional lymph nodes (stage IV) was unresectable. If the oesophageal SCC was not considered unresectable according to the previous NCCN guidelines, this tumour could be regarded resectable, and the patients received surgical treatment. The patients were excluded from this study according to the following exclusion criteria: (1) lost to follow up (n = 26); or (2) with incomplete clinicopathological information (n = 7). Consequently, 197 patients were enrolled into this study in total. According to the published report by Chen et al. [24], all participants were randomly assigned to the training and validation cohorts at the 7:3 ratio. The patient flowchart is shown in Fig. 1.
Archived clinical data, such as gender, age, histological grade, pT staging, pN staging and comprehensive staging were extracted by reviewing the medical records. Tumor staging was judged by the American Joint Committee on Cancer TNM Staging System Manual, 8th Edition [25].

Follow-up
According to the latest edition of the NCCN guidelines [21], asymptomatic oesophageal SCC patients were followed up at 3 to 6 month intervals during the first 2 year, 6–12 month intervals until the fifth year, and then annually. If recurrence was suspected, patients underwent further clinical examinations including CT, ultrasonography, endoscopy, and 18FDG-PET CT for the confirmation of recurrence [9]. In our study, all patients underwent more than one year’s follow-up, and those with suspected recurrent lesions received cervical and thoracoabdominal CT, cerebral CT or magnetic resonance imaging, endoscopic biopsy, and even FDG-PET CT to diagnose the recurrence according to the published report [7–9].

Image acquisition and retrieval procedure
All patients we collected underwent CECT scans with 128 multi-detector scanners (LightSpeed VCT, Ge Medical systems, USA). Patients who were suspected of having oesophageal cancer were required to drink 100–200 ml water before CT, which was used as oesophageal negative contrast material. During the CT examination, the patients were scanned in the supine position and hold a breath for 10–15 s to get satisfactory images. Following routine non-enhanced CT, CECT was performed a 25–30 s delay after intravenous injection of 1.5 mL/kg contrast material (Omnipaque, Iohexol, GE Healthcare, USA) at the rate of 3.0 mL/s with a pump injector (Vistron CT Injection System, Medrad, USA). The parameters for the CT scans were given as follows: 120 kV, 200 mAs, 0.5 s rotation time, detector collimation of 64×0.6 mm, pitch of 0.9, slice thickness of 5.0 mm, and matrix of 512×512 mm. The coverage of CT examination was from the base of skull to the middle of the left kidney. All CECT image data that were used for extracting features were obtained by picture archiving and communication system.

Image segmentation and radiomics feature extraction
The manual segmentation of tumor images (Fig. 2) was performed independently with IBEX (β1.0, http://bit.ly/IBEX_MDAnderson), an open source software, which ran on 64-bit MATLAB 2013Ra [26]. During delineating of the tumorous region-of-interest (ROI), we agreed that the thickness of oesophageal wall exceeding 5 mm was considered abnormal [27, 28]. When the tumor size exceeded 5 mm, we drew each ROI by taking both the tumour size and the abnormal contrast-enhanced area into consideration to determine the tumour area. Two radiologists (readers 1 (ST) and 2 (TWC), with 2 years and 22 years of medical imaging experience in the digestive system, respectively) were blinded to patients’
pathological results. When reader 1 and reader 2 disagreed with each other, they could reach consensus after discussion. For each ROI, the contour of locally advanced oesophageal SCC was delineated slice-by-slice around the lesion avoiding air, fat and bone. Features were extracted from IBEX, and included gray-level co-occurrence matrix (GLCM), gray-level run-length matrix (GLRLM), intensity histogram, and shape. There were 352 radiomics features in total for locally advanced oesophageal SCC to describe the tumor characteristics.

Intra- and inter-observer agreements
In order to guarantee the reproducibility of results, we randomly selected consecutive 50 cases’ CECT data from all patients for intra- and inter-observer consistency testing. The intra-class correlation coefficient (ICC) was an evaluation index to assess intra- and inter-observer agreements. It meant good consistency when the ICC score was greater than 0.75. The ICC of intra-observer was measured by reader 1 drawing the outline of ROI twice within one week following the same steps according to the published report by Chen et al. [24]. In addition, reader 2 independently sketched the ROI of the lesion when reader 1 performed the first delineation, and the results of radiomics features extracted from these two delineations were compared to assess the inter-observer agreement based on the ICC value. Because of the nature of the variability resulting from the voxel-size and gray-level dependency [29], it was impossible that all radiomics signatures met the criteria for satisfactory agreement.

Dimensionality reduction and radiomics feature selection
In order to avoid the curse of dimensionality and reduce the bias from radiomics features during modeling [24], we adopted the following methods to select the unique and optimal features in the training cohort.

First, all the radiomics features extracted from imaging data were processed to z-score normalization (mean is zero and variance is one) [30]: \( x_{\text{norm}} = \frac{x - \mu}{\sigma} \), where \( x \) is the original feature value, \( \mu \) is the mean value of this feature, and \( \sigma \) is the standard deviation.

Second, the independent samples \( t \) test or the Mann-Whitney U test was further used to select potential important features of training cohort. The radiomics features without statistical significance (\( P \)-value > 0.05) were excluded.

Finally, the least absolute shrinkage and selection operator method (LASSO) [29], capable for performing regression analysis on high-dimensional data, was used to select the core radiomics features for predicting early recurrence of oesophageal SCC. The 1-standard error of the minimum criteria (the 1-SE criteria, a simpler model) was used to adjust the regularization parameter (\( \lambda \)) for select feature using 10-fold cross-validation.

Construction of the radiomics model
The optimal selected radiomics features and clinical characteristics were used to construct three predictive models through logistic regression, which was a classical machine learning method. The three predictive models were a radiomics model, a clinical model, and an integration of the radiomics and clinical features. The adjustment of the optimal predictive model followed the same process as described above. The confusion matrix calculated the area under receiver operating characteristic curve (AUC), accuracy, F1 score as well as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to evaluate training results and test results of the three predictive models.

Statistical analysis
All data of radiomics characteristics were conducted through R (Version 3.4.4, https://www.r-project.org/). The “glmnet” package was used to perform LASSO regression, and “pROC” package was used to draw receiver operating characteristic (ROC) curves. Statistical analysis methods varied with the type of clinical characteristics. The normality of distribution was evaluated by Shapiro-Wilk test and the homogeneity of variance was tested by Bartlett test. Continuous variables, expressed as the mean or median, were compared by the independent \( t \)-test. The categorical variables were described in percentiles and compared using the Chi-square test or Fisher’s exact test. \( P < 0.05 \) meant statistical difference.
Results

Clinical characteristics

In our cohort of 197 patients with locally advanced oesophageal SCC, 101 patients recurred whereas the remaining 96 did not. In the 101 patients with recurred oesophageal SCC, the recurrence time was more than 3 months and less than or equal to 6 months after the treatments in 27 patients, more than 6 months and less than or equal to 9 months after the treatments in 39 patients, and more than 9 months and less than or equal to 12 months after the treatments in 35 patients. The clinical characteristics of locally advanced oesophageal SCC in the early recurrence and non–early recurrence dataset are recorded in Table 1. Among the six clinical features listed in Table 1, four clinical features including pT stage, pN stage, differentiation degree and pTNM stage indicated statistical differences between the early recurrence and non–early recurrence of oesophageal SCC (all P-values < 0.05) whereas age and gender were not statistically significant (all P-values > 0.05). All clinical features were used to establish a clinical model.

Intra- and inter-observer agreements

For intra-observer agreement of CT radiomics feature extraction, there were 275 extracted features with ICC greater than 0.75 whereas ICC was not greater than 0.75 for 77 features (Fig. 3a). In terms of inter-observer agreement, there were 263 features with ICC greater than 0.75 while ICC was not greater than 0.75 for 89 features including the previous features with intra-observer ICC of not greater than 0.75 (Fig. 3b). After this assessment, the 89 features were excluded, and the remaining 263 features with intra- and inter-observer ICC values of greater than 0.75 were selected from the 352 extracted features for further analysis, and all results were derived from the feature extraction by reader 1.

Dimensionality reduction and radiomics feature selection

The independent sample t test or Mann-Whitney U test showed that out of 263 features, 249 features were significantly different (all P-values < 0.05). Therefore, 249 features in total were used for LASSO regression, and 11

Table 1 Clinical features of early recurrence and non-early recurrence cohorts

|                      | Early recurrence (n = 101) | Non-early recurrence (n = 96) | P-value |
|----------------------|----------------------------|------------------------------|---------|
| Median age (years)   | 62.5 (40 to 80)            | 63.0 (47 to 78)              | 0.665   |
| Gender (%)           |                            |                              | 0.799   |
| Male                 | 72 (71.3)                  | 70 (72.9)                    |         |
| Female               | 29 (28.7)                  | 26 (27.1)                    |         |
| pT stage (%)         |                            |                              | 0.044*  |
| T1                   | 1 (1.0)                    | 5 (5.2)                      |         |
| T2                   | 30 (29.7)                  | 36 (37.5)                    |         |
| T3                   | 59 (58.4)                  | 52 (54.2)                    |         |
| T4a                  | 11 (10.9)                  | 3 (3.1)                      |         |
| pN stage (%)         |                            |                              | < 0.001*|
| N0                   | 51 (50.5)                  | 74 (77.1)                    |         |
| N1                   | 32 (31.7)                  | 17 (17.7)                    |         |
| N2                   | 18 (17.8)                  | 5 (5.2)                      |         |
| Differentiation degree (%) |                      |                              | 0.017*  |
| Low                  | 2 (1.9)                    | 7 (7.3)                      |         |
| Middle               | 55 (54.5)                  | 35 (36.5)                    |         |
| High                 | 44 (43.6)                  | 54 (56.2)                    |         |
| pTNM stage (%)       |                            |                              | < 0.001*|
| IB                   | 7 (6.9)                    | 20 (20.8)                    |         |
| IIA                  | 25 (24.8)                  | 33 (34.4)                    |         |
| IIB                  | 15 (14.9)                  | 21 (21.9)                    |         |
| IIIA                 | 8 (7.9)                    | 4 (4.1)                      |         |
| IIIB                 | 46 (45.5)                  | 18 (18.8)                    |         |
features were selected by LASSO (22.6:1 ratio) (Fig. 4a and b). These features included six texture features, four shape features, and one intensity histogram feature (Table 2).

Construction of the radiomics model
Through logistic regression, the 11 selected optimal radiomics features and six clinical features were applied to establish three prediction models in predicting early recurrence of locally advanced oesophageal SCC including a radiomics model, a clinical model, and a model that integrated radiomics and clinical characteristics. The most suitable model was selected by AUC, accuracy, and F-1 score together with sensitivity, specificity, PPV, NPV as shown in Table 3. Similarly in the pattern of ROC curves in the published literature [18], the ROC curves (Fig. 5a and b) visually indicated the integration model of radiomics and clinical features was superior to radiomics or clinical model in predicting early recurrence of locally advanced oesophageal SCC in the training cohort (AUC: 0.821 versus 0.754 or 0.679; and F1-score: 0.730 versus 0.690 or 0.671) and in the validation cohort (AUC: 0.809 versus 0.646 or 0.658; and F1-score: 0.778 versus 0.631 or 0.567, respectively). The DeLong test showed that the combined model of radiomics and clinical features was statistically better than the radiomics model or the clinical model in predicting early recurrence of locally advanced oesophageal SCC after trimodal therapy.

Our study shows that pT stage, pN stage, pTNM stage and differentiation degree are independent clinical risk factors of early recurrence in locally advanced oesophageal SCC patients whereas age and gender are not among the six clinical characteristics which are used to establish the clinical model. As reported, the pT stage, pN stage and pTNM stage may be related to invasive depth of the tumor itself and the extent of lymphatic vessel invasion [7, 35]. As for differentiation degree, previous literature has shown that it is closely related to that tumor aggressiveness, but it is controversial whether the differentiation degree affects the prognosis of

Discussion
Radiomics is a nascent image analysis method by extracting a large number of quantitative features to quantify tumor heterogeneity based on imaging data, which is of great significance for personalized oncology [31–33]. Radiomics has been attracting much attention because of its potential predictive power for treatment outcomes and cancer genetics in personalized medicine [34]. In this study, we have developed and validated a radiomics model based on the CECT images to predict the early recurrence of locally advanced oesophageal SCC after trimodal therapy.

The discussion section could provide further insights and implications of the findings, potential applications, and future research directions.
patients with oesophageal cancer [36, 37]. This study shows that when limited to locally advanced oesophageal SCC, the degree of differentiation has a certain relationship with early recurrence. However, the value of the clinical model in our study is limited in the prediction of early recurrence of locally advanced oesophageal SCC, with AUC values of 67.9% in the training cohort and 65.8% in the test cohort.

As shown in this paper, we selected 11 most unique features from all 352 features to build the CT radiomics model. The 11 features include texture features, intensity histogram features and shape features, which could be useful for assessing early recurrence of locally advanced oesophageal SCC. The six texture features and one intensity histogram feature include X45.7 Difference Entropy, X135.7 Dissimilarity, X0.1 Information Measure Corr1, X90.7 Information Measure Corr2, X45.7 Inverse Variance, X90 High Gray Level Run Empha, and Kurtosis. They can mainly represent the texture characteristics of tumors, which are highly associated with the heterogeneity and prognosis of the tumour [37, 38]. Shape features of Compactness1, Mass, Orientation, and Roundness provide the external features about the contours of the tumour. Our CT radiomics model shows a moderate performance in both the training cohort and the test cohort, with AUC values of 75.4 and 64.6%, respectively, indicating that the clinical application of the radiomics model plays a certain role in capturing the intra-tumour heterogeneity information and alerting patients to potential recurrence [20].

The combined model obtains more satisfactory predictive results (with AUC values of 0.821 and 0.809 in training and test cohorts, respectively) compared with the other two models. It can be explained by the fact that the clinical and radiomics features complement each other to improve the predictive power of the combined model [16, 39, 40].

According to relevant literature [20, 41, 42], though radiomics has been applied to predict recurrence of many malignancies including liver cancer, rectal cancer and bladder cancer, methods for predicting the early recurrence of locally advanced oesophageal SCC after trimodal therapy based on CECT images are still lacking. We have built and verified the radiomics model to

| Feature category         | Features of early recurrence vs. non-early recurrence |
|-------------------------|------------------------------------------------------|
| Texture features        | X45.7 Difference Entropy, X135.7 Dissimilarity, X0.1 Information Measure Corr1, X90.7 Information Measure Corr2, X45.7 Inverse Variance, X90 High Gray Level Run Empha, and Kurtosis. |
| GLCM                    | X45.7 Difference Entropy, X135.7 Dissimilarity, X0.1 Information Measure Corr1, X90.7 Information Measure Corr2, X45.7 Inverse Variance, X90 High Gray Level Run Empha, and Kurtosis. |
| GLRLM                   | X45.7 Difference Entropy, X135.7 Dissimilarity, X0.1 Information Measure Corr1, X90.7 Information Measure Corr2, X45.7 Inverse Variance, X90 High Gray Level Run Empha, and Kurtosis. |
| Shape features          | Compactness1, Mass, Orientation, and Roundness. |
| Intensity histogram     | Kurtosis. |

Notes: GLCM, Gray-level co-occurrence matrix; and GLRLM, Gray-level run-length matrix. GLCM features have been constructed by four directions (θ = 0°, 45°, 90°, and 135°) and three offsets (d = 1, 4, 7); and GLRLM features have been constructed by two directions (θ = 0°, 90°) and one offset (d = 1).

Table 3 The performance of the three constructed models to predict early recurrence of locally advanced oesophageal squamous cell carcinoma

| Cohort                | Prediction model                                      | AUC  | ACC  | F1-score | Sen  | Spe  | PPV  | NPV  |
|-----------------------|-------------------------------------------------------|------|------|----------|------|------|------|------|
| The training cohort   | Integrated model of radiomics and clinical features    | 0.821| 0.730| 0.730    | 0.735| 0.725| 0.725| 0.735|
|                       | The radiomics model                                   | 0.754| 0.682| 0.690    | 0.694| 0.662| 0.694| 0.662|
|                       | The clinical model                                    | 0.679| 0.671| 0.671    | 0.592| 0.606| 0.652| 0.544|
| The validation cohort | Integrated model of radiomics and clinical features    | 0.809| 0.733| 0.778    | 0.761| 0.720| 0.718| 0.762|
|                       | The radiomics model                                   | 0.646| 0.630| 0.631    | 0.655| 0.613| 0.613| 0.655|
|                       | The clinical model                                    | 0.658| 0.667| 0.567    | 0.417| 0.722| 0.500| 0.650|

Notes: AUC, Area under the receiver operating characteristic curve; ACC, Accuracy; Sen, Sensitivity; Spe, Specificity; PPV, Positive predictive value; and NPV, Negative predictive value.
predict the early recurrence of locally advanced oesophageal SCC after trimodal therapy by taking the following measures to ensure the robustness. Firstly, as reported by Tan et al., it is reasonable to select oesophageal cancer lesions exceeding 5 mm for radio-mics feature extraction [43]. We performed our radio-mics study based on the referenced criteria that the thickness of oesophageal wall exceeding 5 mm was considered abnormal [27, 28]. As for radiomics analysis on the tumour exceeding 5 mm, we drew each ROI by taking both the tumour size and the abnormal contrast-enhanced area into consideration to determine the tumour area. Secondly, we used the reported CT scanning protocol to acquire the image data. According to the CT data acquisitions in the published radiomics research on oesophageal cancer [17], we deliberately selected early arterial phase images which were obtained 25–30 s after intravenous injection of the contrast material. Thirdly, to avoid overfitting the data, we set up test cohort to verify the ability of the radiomics model to predict early recurrence of locally advanced oesophageal SCC [20]. Last but not the least, univariate analysis, LASSO and Spearman correlation tests were used to guarantee the optimality and independence of each feature in the final model. Due to select optimal feature and modeling, we used 10-fold cross validation and stepwise regression to ensure the robustness of the model [29].

There are still some limitations in our retrospective study. First of all, this study is a relatively small sample and single-center study, and the applicability and universality of our findings needs to be further verified. Despite this limitation, our sample size was larger than that in the published reports focusing on radiomics study of oesophageal cancer [44, 45], suggesting that the relatively small sample in our study could still help obtain reliable results. Secondly, more studies are needed to demonstrate whether more clinical features can be considered in a comprehensive evaluation. Thirdly, previous studies have shown that thin-slice CT images can better display texture characteristics of tumours than thick-slice CT images [46]. It still remains to be verified whether thin slice CT images can increase the predictive power of the radiomics model.

**Conclusions**

Our study explored the radiomics approach based on CECT images as a feasible method to predict early recurrence of locally advanced oesophageal SCC after trimodal therapy. The model by integrating CECT radiomics and clinical features can further improve the predictive performance of early recurrence of locally advanced oesophageal SCC when compared to the radiomics model or clinical model. We hope that our integrated model can be helpful for selecting the patients with high risk of early recurrence as early as possible to undergo effective personalized treatment and closer follow-up to prevent early recurrence of this cancer.

**Abbreviations**

SCC: Squamous cell carcinoma; CECT: Contrast-enhanced computed tomography; CT: Computed tomography; ROI: Region of interest; AUC: Area under the receiver operating characteristic curve; NCCN: National Comprehensive Cancer Network; GLCM: Gray-level co-occurrence matrix; GLRLM: Gray-level run-length matrix; ICC: Intra-class correlation coefficient; LASSO: Least absolute shrinkage and selection operator; ROC: Receiver operating characteristic; PPV: Positive predictive value; NPV: Negative predictive value

**Acknowledgements**

The authors thank Dr. Xin Li and Dr. Zhou-she Zhao from GE Healthcare, who are experts in radiomics modeling, for teaching us how to perform data analysis and reviewing our findings.

**Authors’ contributions**

TWC, RL, CQW, XMZ and JH proposed the study. JO, RZ, YC, LW, YJ, JQY, JMC, ST and JMC performed research, and collected the data. JO and TWC analyzed the data and wrote the first draft. All authors contributed to the interpretation of the study and to further drafts. All authors read and approved the final manuscript. TWC is the guarantor. JO and RL contribute equally to this work.

**Funding**

This work was supported by the National Natural Science Foundation of China (grant no. 81571645), the Sichuan Province Special Project for Youth Team of Science and Technology Innovation (grant no. 2015STD0029), and...
the Construction Plan for Scientific Research Team of Sichuan Provincial Colleges and Universities (grant no. 1STD0023).

Availability of data and materials
Please contact the corresponding author for data requests.

Declarations

Ethics approval and consent to participate
This retrospective study was approved by the institutional review board of the Affiliated Hospital of North Sichuan Medical College. Due to a retrospective study, the patient consent for the study was waived.

Consent for publication
All authors gave consent for the publication of this paper.

Competing interest
All authors declare that they have no competing interests in this study.

Author details
1Sichuan Key Laboratory of Medical Imaging, Department of Radiology, Affiliated Hospital of North Sichuan Medical College, 63# Wenhua Road, 637000 Nanchong, Sichuan, China. 2Sichuan Key Laboratory of Medical Imaging, North Sichuan Medical College, Nanchong, Sichuan, China. 3Department of Radiology, Wayne State University, Detroit, Michigan, USA.

Received: 27 January 2020 Accepted: 12 May 2021
Published online: 26 May 2021

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
4. Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, et al. Evaluation of prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy followed by surgery. World J Surg. 2013;37:1496–505.
5. Hamai Y, Hihara J, Emi M, Murakami Y, Kenjo M, Nagata Y, et al. Results of neoadjuvant chemoradiotherapy with docetaxel and S-Fuorouracil followed by esophagectomy to treat locally advanced esophageal cancer. Ann Thorac Surg. 2015;99:1887–90.
6. Murakami Y, Hamai Y, Emi M, Hihara J, Imano N, Takeuchi Y, et al. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res. 2018;59:616–24.
7. Zhu ZJ, Hu Y, Zhao YF, Chen XZ, Chen LQ, Chen YT. Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91:1502–8.
8. Hamai Y, Emi M, Ikibu Y, Murakami Y, Nishibuchi I, Nagata Y, et al. Early recurrence and cancer death after trimodal therapy for esophageal squamous cell carcinoma. Anticancer Res. 2019;39:1433–40.
9. Sugiyama M, Morita M, Yoshiida R, Ando K, Egashira A, Takefumi O, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.
10. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:881–92.
11. Tepper J, Kransa MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase II trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.
12. Van Hagen P, Hulshof MC, van Lanschot JI, Steyerberg EW, van Berge, Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or gastroesophageal junction cancer. N Engl J Med. 2012;366:2074–84.
13. Yamabe Y, Kuroki Y, Ishikawa T, Miyakawa K, Kuroki S, Sekiguchi R. Tumor staging of advanced esophageal cancer: combination of double-contrast esophagography and contrast-enhanced CT. AJR Am J Roentgenol. 2008;191:753–7.
14. Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. Methods Mol Biol. 2011;727:39–76.
15. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.
16. Gillies RJ, Khanahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016;278:563–77.
17. Wu L, Wang C, Tan Y, Cheng Z, Zhao K, Yan L, et al. Radiomics approach for preoperative identification of stages I-II and III-IV of esophageal cancer. Chin J Cancer Res. 2018;30:396–405.
18. Shen C, Liu Z, Wang Z, Guo J, Zhang H, Wang Y, et al. Building CT radiomics based nomogram for preoperative esophageal cancer patients lymph node metastasis prediction. Transl Oncol. 2018;11:815–24.
19. Larue RTHM, Klaassen R, Jobachs A, Leijenaar RTH, Hulshof MCM, van Berge, et al. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncol. 2018;57:1475–81.
20. Ning P, Gao F, Hai J, Wu M, Chen J, Zhu S, et al. Application of CT radiomics in prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY). 2020;45:64–72.
21. Amani JA, D’amico TA, Bentrem DJ, Farjah F, Gerdes H, Gibson M, et al. Esophageal and esophagogastrectomy junction cancers. Version 2.2019, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:855–85.
22. Li H, Chen TW, Zhang XM, Li ZL, Chen XL, Tang HJ, et al. Computed tomography scan as a tool to predict tumor T category in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 2013;95:1749–55.
23. Salo JA, Scott WJ, Watson TJ, Allen MS, Chen LQ, Rusch WV, et al. Esophageal Cancer: Associations With (pH+) Lymph Node Metastases. Ann Surg. 2017;265:122–9.
24. Chen Y, Chen TW, Wu CQ, Lin Q, Hu R, Xie CL, et al. Radiomics model of contrast-enhanced computed tomography for predicting the recurrence of acute pancreatitis. Eur Radiol. 2019;29:4408–17.
25. Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the Esophagus and Esophagogastrectomy Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2017;12:36–42.
26. Zhang L, Fried EV, Faye XJ, Hunter LA, Yang J, Court LE. IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med Phys. 2015;42:1341–53.
27. Desai RK, Taglabue JR, Wegyn SA, Einstein DM. CT evaluation of wall thickening in the alimentary tract. Radiographics. 1991;11:771–83. discussion 784.
28. Dionigi G, Rovera F, Boni L, Bellani M, Baccuzzi A, Caraffiello G, et al. Cancer of the esophagus: the value of preoperative patient assessment. Expert Rev Anticancer Ther. 2006;6:581–93.
29. Shafigh-Ul-Hassan M, Zhang GG, Latifi K, Ullah G, Hunt DC, Balagurunathan Y, et al. Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. Med Phys. 2017;44:1050–62.
30. Cheadle C, Vawter MP, Frewel WJ, Becker KG. Analysis of microarray data using z score transformation. J Mol Diagn. 2003;5:73–81.
31. Bi WL, Hosny A, Schabath MB. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69:127–57.
32. Lambin P, Leijenaar RTH, Deist TM. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.
33. Ji GW, Zhang YD, Zhang H, Zhu FP, Xia YX, et al. Biliary tract cancer PRIMERA Primer. J Thorac Oncol. 2017;12:36–42.
34. Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2015;60:R239–69.
35. Morita M, Kurano H, Ohno S, Furusawa M, Sugimachi K. Characteristics and sequence of the recurrent patterns aftercurative esophagectomy for squamous cell carcinoma. Surgery. 1994;116:1–7.
36. Chisteanu JD, Hollinger EF, Millikan KW. Prognostic factors associated with resectable carcinoma of the esophagus. Am Surg. 2002;68:258–62; discussion 262–263.
37. Zafirellis K, Dolan K, Fountoulakis A, Dexter SP, Martin IG, Sue-Ling HM. Multivariate analysis of clinical, operative and pathologic features of esophageal cancer who needs adjuvant therapy? Dis Esophagus. 2002;15:155–9.
38. Ng F, Ganeshan B, Kozarski R, Miles KA, Goh V. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology. 2013;266:177–84.

39. Permutt JB, Choi J, Balunathan Y, Kim J, Chen DT, Chen L, et al. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016;7:85785–97.

40. Zhang B, Tian J, Dong D, Gu D, Dong Y, Zhang L, et al. Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res. 2017;23:4259–69.

41. Jeon SH, Song C, Chie BK, Kim B, Kim YH, Chang W, et al. Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. Radiat Oncol. 2019;14:43.

42. Xu X, Wang H, Du P, Zhang F, Li S, Zhang Z, et al. A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors. J Magn Reson Imaging. 2019;50:1893–904.

43. Tan X, Ma Z, Yan L, Ye W, Liu Z, Liang C. Radiomics nomogram outperforms size criteria in discriminating lymph node metastasis in resectable esophageal squamous cell carcinoma. Eur Radiol. 2019;29:392–400.

44. Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart RHJ, et al. Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging 18F-FDG PET imaging biomarkers in patients with esophageal cancer. Radiology. 2018;287:983–92.

45. Jin X, Zheng X, Chen D, Jin J, Zhu G, Deng X, et al. Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics. Eur Radiol. 2019;29:6080–8.

46. Zhao B, Tan Y, Tsai WY, Qi J, Xie C, Lu L, et al. Reproducibility of radiomics for deciphering tumor phenotype with imaging. Sci Rep. 2016;6:23428.

47. Sauterbee W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26:5512–28.

48. Yip C, Davnall F, Kozarski R, Landau DB, Cook GI, Ross P, et al. Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. Dis Esophagus. 2015;28:172–9.

**Publisher's Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.